Table S1. Summary of Included Studies of Lumefantrine Pharmacokinetics in Plasmodium Falciparum

Table S1. Summary of included studies of Lumefantrine pharmacokinetics in Plasmodium falciparum malaria patients.

Study Description Assay Methodology LLOQ Country Study Site Year N1/N2* A Method Laboratory (ng/ml) 6 doses over 3 days Bioanalytics and Pharmacoki netics 2006- department, EDPJN [44] Benin 10/110 4 LC-MS/MS 50 2007 ( Novartis Pharma, Rueil Benin Malmaison, France Saint-Louis Hospital biochemistr YYDSM [43] Allada, Sekou 2007 44/96 2 HPLC-UV [47] 20 ( y laboratory, Paris, France. Cambodia REQES [12] Battambang 2003- 79/79 2 HPLC-UV 45] 24 Clinical 2004 ( Pharmacolo gy Laboratory, Mahidol- Oxford Tropical Medicine Research Unit, Thailand Bioanalytics and Pharmacoki Guinea Bandim, 2007- netic SXGQP [34] 122/191 7 HPLC-UV [47] 52.9 Bissau Belem, Cutum 2008 ( laboratory, Dalarna University, Sweden Bioanalytics and Pharmacoki netics 2006- department, EDPJN [44] Kenya 12/192 2 LC-MS/MS 50 2007 ( Novartis Pharma, Rueil Malmaison, France Kenya Clinical Pharmacolo gy Laboratory, Mahidol- QZJGM [39] Battambang 2005 101/241 3 HPLC-UV [51] 1.5 Oxford ( Tropical Medicine Research Unit, Thailand Laos HKNHR [41] Phalanxay 2002 77/110 1 HPLC-UV [51] 24 Clinical District ( Pharmacolo gy Laboratory, Mahidol- Oxford Tropical Medicine Research Unit, Thailand Service de Pharmacolo gie Clinique, 2008- FEDZY [28] Nimba County 438/502 1 HPLC-UV [47,49] 200 Hospital St. 2009 ( Vincent de Paul, Paris, France Liberia Service de Pharmacolo gie Clinique, 2008- UBTXH [38] Nimba County 106/150 3 HPLC-UV [47,49] 200 Hopital St. 2009 ( Vincent de Paul, Paris, France Bioanalytics and Pharmacoki netics department, Mali EDPJN [44] Mali 2006 8/225 3 LC-MS/MS 50 ( Novartis Pharma, Rueil Malmaison, France Mozambique EDPJN [44] Mozambique 2006 11/102 3 LC-MS/MS 50 Bioanalytics and Pharmacoki netics department, ( Novartis Pharma, Rueil Malmaison, France School of Medicine and Pharmacolo RAJDQ [35] Madang 2007 11/13 8 HPLC – UV [50] 5 gy, ( University of Western Australia, Papua New Australia Guinea School of Medicine and Pharmacolo Madang, East UANQM [33] 2005 95/128 3 HPLC-UV [48] 5 gy, Sepik ( University of Western Australia, Australia Tanzania EDPJN [44] Tanzania 2006- 19/269 3 LC-MS/MS 50 Bioanalytics 2007 ( and Pharmacoki netics department, Novartis Pharma, Rueil Malmaison, France Bioanalytics and Pharmacoki Fukayosi, 2007- netic GZQDA [32] 353/359 3 HPLC-UV [47] 25 Yombo 2008 ( laboratory, Dalarna University, Sweden Bioanalytics and Pharmacoki Fukayosi, 2007- netic KGHRT [32] 152/168 3 HPLC-UV [47] 25 Yombo 2008 ( laboratory, Dalarna University, Sweden UHUBT [42] Kilombero 2008 128 [3]/143 1 LC-MS/MS [49] 3 Division of District ( Clinical Pharmacolo gy, Department de Medicine, University Hospital and University of Lausanne, Lausanne, Switzerland Bioanalytics and Pharmacoki Fukayosi, netic XXFCZ [31] 2007 177/244 3 HPLC-UV [47] 35 Yombo ( laboratory, Dalarna University, Sweden Novartis 1997- Pharma, SMRU 66/86 2 HPLC-UV [46] 40 KGJRP [27] 1998 ( Basel, Switzerland Novartis 1996- Pharma, RGPFA [7] Bangkok 18/32 3 HPLC-UV [46] 40 1997 ( Basel, Switzerland Novartis SAUSX SMRU, Pharma, 1997 134/147 2 HPLC-UV [46] 40 [11,30] Bangkok ( Basel, Thailand Switzerland Clinical Pharmacolo gy Laboratory, Mahidol- USGDC [40] SMRU 2002 16/16 3 HPLC-UV [51] 25 Oxford ( Tropical Medicine Research Unit, Thailand Uganda CCEPC [37] Mbarara 2002- 448 [1]/957 9 HPLC-UV [48] 5 Bioanalytics 2004 ( and Pharmacoki netics department, Novartis Pharma, Rueil Malmaison, France Clinical Pharmacolo gy Laboratory, Mahidol- DBCXT [5,29] 2007- Kampala 20/579 9 HPLC-UV [51] 25 Oxford 2008 ( Tropical Medicine Research Unit, Thailand 3 doses over 3 days Clinical Pharmacolo gy Laboratory, Mahidol- Thailand USGDC [40] SMRU 2002 19/19 2 HPLC-UV [51] 25 Oxford ( Tropical Medicine Research Unit, Thailand 4 doses over 2 days Thailand FMNNB [36] SMRU 1996 43/302 2 HPLC–UV [7] 40 Novartis Pharma, ( Basel, Switzerland Novartis 1996- Pharma, KGJRP [27] Bangkok 69/85 2 HPLC–UV [46] 40 1997 ( Basel, Switzerland Novartis 1996- Pharma, RGPFA [7] Bangkok 15/33 2 HPLC-UV [46] 40 1997 ( Basel, Switzerland LLOQ: Lower Limit of Quantification; SMRU: Shoklo Malaria Research Unit, LC-MS/MS: liquid chromatography coupled with tandem mass spectrometry; HPLC-UV: High-pressure liquid chromatography with ultraviolet visible detection. N1/N2 =number of patients in PK study; N2= number of all patients in the study; number in brackets shows number of pregnant women